Dare Bioscience, Inc. annual report, FY2018

Daré Bioscience, Inc. — FY 2018 Form 10-K

Reporting period: Fiscal year ended December 31, 2018. This is an annual report, not a standalone fourth-quarter filing. Comparisons with 2017 are limited because the July 2017 Cerulean/Private Daré transaction changed the business and the 2017 results include pre- and post-transaction periods.

Business context

Daré is a clinical-stage women’s health biopharmaceutical company with no approved products, product sales, or product revenue. Its four clinical-stage candidates are DARE-BV1 for bacterial vaginosis, Ovaprene for non-hormonal contraception, Sildenafil Cream 3.6% for female sexual arousal disorder, and DARE-HRT1 for menopausal symptoms. It also holds rights to several pre-clinical programs. Development and commercialization depend substantially on licensed intellectual property and third parties.

Financial results and liquidity

MetricFY 2018FY 2017
Revenue$0$0
Research and development expense$6.41 million$0.98 million
General and administrative expense$4.66 million$2.70 million
Goodwill impairment$5.19 million$7.49 million
Net loss$16.74 million$11.50 million
Net cash used in operating activities$10.27 million$2.54 million

Research and development expense increased 551%, largely reflecting higher candidate development costs and portfolio-building activity. General and administrative expense increased 72%, including higher personnel, public-company, professional-services, and insurance costs. The 2018 goodwill impairment eliminated the remaining goodwill balance. Loss per share was $1.57 in 2018 versus $3.56 in 2017; weighted-average shares increased to 10.73 million from 3.23 million, so per-share comparison is affected by the larger share count.

At year-end, cash and cash equivalents were $6.81 million, working capital was $6.1 million, total current assets were $7.24 million, and current liabilities were $1.09 million. Total liabilities were $1.10 million; the balance sheet reports no debt. Stockholders’ equity was $6.73 million. Cash decreased by $0.75 million during the year: operating cash use of $10.27 million and investing cash use of $0.52 million were largely offset by $10.11 million of financing proceeds. The company raised approximately $11.3 million gross, or $10.1 million net, through equity offerings and at-the-market sales.

Management and the independent auditor each reported substantial doubt about the company’s ability to continue as a going concern. Management estimated year-end cash would fund planned operations into the third quarter of 2019, while also stating that available resources were insufficient for working-capital and liquidity needs over at least the 12 months following the financial statements’ issuance. Further capital is required; no assurance is given that it will be available on acceptable terms.

Material changes, outlook, and risks

  • In 2018, Daré added or advanced programs through licensing and acquisition activity, including the DARE-BV1 hydrogel rights, Juniper’s vaginal-ring technology, the Sildenafil Cream license, Pear Tree assets, and an option collaboration for long-acting injectable contraceptives.
  • DARE-BV1: A 30-participant investigator-initiated pilot reported an 88% clinical cure rate among 26 evaluable participants. The company planned an approximately 250-woman Phase 3 study in Q4 2019 and, if successful, an NDA filing in 2020. Management estimated the Phase 3 study, manufacturing, and subsequent filing would cost less than $10 million.
  • Ovaprene: The postcoital study was ongoing, with results expected in the second half of 2019. The NIH awarded an additional $982,851 in March 2019, subject to eligible expenses; a further $730,722 of the anticipated grant remained contingent. U.S. marketing is expected to require a PMA, and requirements may prove more extensive than anticipated.
  • Sildenafil Cream 3.6%: Phase 2b planning included a patient-reported-outcome study and further FDA consultation. Timing of the planned at-home Phase 2b trial depends on study findings and FDA guidance.
  • DARE-HRT1: The company planned a Phase 1 study in 2019, with topline results expected in 2020. The ring technology had not yet been tested in women.

Key risks include continued losses and financing dependence; dilution and restrictive warrant anti-dilution terms; uncertain clinical outcomes, regulatory pathways, timelines, and costs; reliance on licensors, contract manufacturers, CROs, and potential commercial partners; limited or single-source supply for some Ovaprene components; competition, generic pricing, reimbursement, and market acceptance; and intellectual-property and license-termination risks. The February 2018 warrants covered up to 3.72 million shares and had a $3.00 exercise price at March 29, 2019, with price-based anti-dilution provisions. Daré reported regaining Nasdaq’s minimum bid-price compliance on March 29, 2019; continued listing remains a risk. No material pending legal proceeding was reported. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation.

Most important facts for investors to verify

  • Current cash, burn rate, financing activity, and runway relative to the stated need for substantial additional capital.
  • Whether planned clinical milestones occurred, especially DARE-BV1 Phase 3 timing and Ovaprene study results, and what the FDA requires for each program.
  • Whether the NIH grant’s contingent amounts are earned and reimbursed, and whether the DARE-BV1 cost estimate remains achievable.
  • Potential dilution from future equity issuance, outstanding options and warrants, and the February 2018 warrants’ anti-dilution provisions.
  • Material license obligations, milestone and royalty exposure, and the risk of losing licensed development rights.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.